Data as of Q4 2025 (Dec 31, 2025)

The Oncology Institute, Inc.

(TOI)

Financial Statements · SEC EDGAR XBRL

Revenue
$502.7M
+27.8%
Net Income
$60.61B
-6.3%
EPS
$-0.54
+23.9%
Op. Income
-$36.1M
+40.0%
FCF
-$27.8M
+8.4%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Revenues
Total Revenues
Operating Expenses & Income
Selling General & Admin
Operating Income
Non-Operating Income/Expense
Interest Income/Expense
Other Non-Operating Income
Pre-Tax Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
$502.7M
$393.4M
$324.2M
$252.5M
$203.0M
$502.7M
$393.4M
$324.2M
$252.5M
$203.0M
$105.6M
$107.8M
$113.9M
$119.7M
$83.4M
-$36.1M
-$60.1M
-$77.0M
-$82.0M
-$45.9M
-
-
-
-
$320K
-$24.7M
-$4.5M
-$6.1M
$81.9M
$34.3M
-$60.7M
-$64.7M
-$83.1M
-$91K
-$11.6M
-$131K
$0
-$36K
-$243K
-$671K
$60.61B
$64.66B
-$83.1M
$152K
-$10.9M
$-0.54
$-0.71
$-0.92
$0.00
$-0.16
$-0.54
$-0.71
$-0.92
$-0.21
$-0.16
92.4M
75.0M
73.7M
80.6M
66.2M